Aligos Secures $25M Upfront in China HBV Drug Deal, Extends Cash Runway
ALGS has more than doubled off its 52-week low of $4.13 on elevated volume (3.4× avg).
Summary
Aligos Therapeutics has entered into an exclusive license agreement with Xiamen Amoytop Biotech Co., Ltd. for its lead chronic Hepatitis B Virus (HBV) drug candidate, pevifoscorvir sodium, in Greater China. The deal includes a significant $25 million upfront payment, up to $420 million in potential clinical, regulatory, and sales milestones, and tiered high single-digit royalties on net sales. This substantial upfront payment is highly material for Aligos, which has a market capitalization of approximately $46 million, and directly addresses the 'going concern' warning from its last 10-K by extending its cash runway from Q3 2026 into Q4 2026. This partnership, following the recent FDA Fast Track designation for pevifoscorvir sodium, strategically positions the drug for development and commercialization in a key market with a high HBV prevalence, leveraging Amoytop's leadership in the region. Investors will now watch for the conditional approval from Amoytop's shareholders and further progress in the Phase 2 B-SUPREME study, with interim analysis expected in H2 2026.
At the time of this announcement, ALGS was trading at $8.50 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $45.9M. The 52-week trading range was $4.13 to $13.69. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: GlobeNewswire.